Buying Immunotherapy Medicines Outside the Hospital: Risks and Rules
Families routinely ask whether an immunotherapy vial can be bought from an outside pharmacy for less than the hospital charges. It is a fair question, and the honest answer has three parts: what the law allows, what can go wrong with a refrigerated biologic bought outside a traceable supply chain, and what paperwork decides whether the money is ever reimbursed. This page sets out all three, without telling anyone what to do.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
Is it allowed to buy immunotherapy medicines outside the hospital?
Yes, with conditions. Immunotherapy medicines are prescription-only drugs under the Drugs and Cosmetics Rules, 1945. Any pharmacy holding a valid retail drug licence may dispense them against a valid prescription from a registered medical practitioner. Buying from a licensed pharmacy that is not the hospital's own is lawful. Buying from anyone without that licence is not.
The second half of the question is separate, and families often collapse the two. A hospital generally cannot compel a patient to buy only from its in-house pharmacy. Regulators and courts have pushed back on that practice repeatedly, and the Maharashtra FDA issued an order to that effect on 12 June 2026, with the Supreme Court raising the same issue with central and state governments in reported hearings. The position is not identical in every state, so it is worth confirming what applies locally.
But whether a day-care unit will infuse a vial you bring in is a hospital policy question, not a legal one. The unit that administers the drug carries the clinical responsibility for it. Many oncology day-care units will not administer a refrigerated biologic whose storage history they cannot verify, and they are entitled to that position. Ask the unit what it accepts before spending anything. A vial already bought cannot be returned if the answer is no.
CDSCO licenses and regulates the sale of these medicines. Nothing on this page is legal advice, and nothing here should be read as CION stating that it supplies, stocks or sources any named product.
Did you know?
In June 2025 the Delhi drugs control department seized more than 160 samples of suspected cancer medicines in a citywide operation, with six arrests. One raid alone recovered 519 empty vials and 864 empty cartons. Investigators described empty vials being taken from hospital treatment rooms, refilled with unknown solutions, resealed with replica labels and sold back into the supply chain — reported by The New Indian Express, 14 July 2025.
What are the risks of buying immunotherapy outside the hospital?
Three risks matter, and they compound. Authenticity, cold chain and traceability. Each one is survivable on its own. Together, they are the reason a saving on paper can become a wasted cycle of treatment that nobody can prove went wrong.
| Risk | What actually goes wrong | What reduces it |
|---|---|---|
| Counterfeit or refilled vial | Genuine empty vials refilled with inert solution and resealed with replica labels. Reported cases in Delhi in March 2024 and June 2025 involved exactly this method, and the vials were described as indistinguishable to patients and pharmacists. | A licensed pharmacy with an audited stock register, an intact carton seal, and a printed invoice naming batch and expiry. |
| Broken cold chain | These are refrigerated biologics stored at 2 to 8 degrees Celsius. A vial carried in a shopping bag, left in a car, or frozen is unsafe even when it is genuine, and nothing about it looks different. | A validated cold box with a temperature record, and the shortest possible time between counter and day-care fridge. |
| No traceability | If there is a batch recall, or a severe reaction, or a claim dispute, there is no way to establish where the vial came from without an invoice tied to a licence number. | A GST tax invoice in the patient's name, kept with the treatment file for the full course. |
| Day-care unit declines to infuse it | The vial is bought, the money is spent, and the unit will not accept a biologic it cannot trace. This is a common and avoidable outcome. | Ask the unit for its written position before purchase, not after. |
| Claim or scheme rejection | A drug bought privately often falls outside a cashless package altogether, or is rejected for want of an original invoice in the patient's name. | Confirm with the billing desk and the insurer in advance, in writing. |
| Imported or unapproved stock | Vials labelled "Not for Sale in India", or brought in by a relative from abroad, sit outside the Indian regulatory chain and cannot be verified here. | Indian-market stock, from an Indian licensed pharmacy, with Indian labelling. |
Counterfeit case details are from published reporting on Delhi Police and Delhi drugs control department actions, March 2024 and June 2025. Storage temperature ranges follow the manufacturer's labelling for each product — our page on why cold chain matters for immunotherapy medicines goes into what a break actually does.
If the price is far below market, why is that a warning sign?
Because that gap is how the reported counterfeit trade worked. The New Indian Express reported in July 2025 that genuine branded biologic doses retail at roughly ₹1.5 to ₹2 lakh, while counterfeit refills were being offered at roughly ₹50,000 to ₹70,000 per vial. The discount was the sales pitch. Those are reported figures, July 2025, and indicative only, as of August 2026.
This is painful to read for a family that is short of money, so it needs saying carefully. A lower price is not proof of anything. A modest difference between two licensed pharmacies is ordinary commerce. A price that is a third of what every hospital quotes, offered by a seller with no shopfront and no invoice, is a different thing entirely.
There is a legitimate cheaper route, and it runs through the pharmacy rather than around it. Indian biosimilars of checkpoint inhibitors are approved and marketed here, and the first domestic nivolumab biosimilar launched on 22 January 2026 at manufacturer-announced prices around one quarter of the reference brand. That saving is available with a full invoice, an intact cold chain, and a day-care unit that will accept the vial. Our pages on which immunotherapy medicines have Indian biosimilars today and the originator versus biosimilar price comparison by molecule set out what exists and what it costs.
All prices quoted on this page come from published manufacturer announcements and reported news, named and dated. They are indicative only, as of August 2026, and they are not CION rates for any named product.
Who this is not for
Most people with cancer in India are not candidates for immunotherapy at all, and a cheaper vial does not change that. Checkpoint inhibitors are approved for a defined set of cancers, and within those, eligibility turns on stage, on what treatment came before, and in some cancers on a biomarker result. If an oncologist has not prescribed immunotherapy, no purchasing route on this page is relevant. Sourcing a drug is never a substitute for the decision to use it.
Outside purchase is also not a workable option in several specific situations, and it is better to know that before spending. It does not work where the treating day-care unit has a written policy against administering patient-supplied refrigerated biologics. It does not work where treatment is being delivered under a cashless scheme package that already includes the drug, because the private purchase simply falls outside the package. It does not work where the only supply available is an unlabelled vial, a vial marked "Not for Sale in India", or stock offered by an individual, an agent or an online listing with no drug licence — no amount of documentation makes that supply safe.
This page is not a price quote, not a source list, not an offer to supply any product, and not a statement that CION stocks or sells any named medicine. It makes no comparative claim about the quality of any manufacturer's product. Whether immunotherapy has a role in a particular patient's treatment, and where the medicine should come from, are decisions for the treating oncologist and the hospital pharmacy team.
What documentation is needed if you buy outside?
Six documents, collected in order, before the vial leaves the counter. Each one exists for a reason that only becomes obvious when something goes wrong — a recall, a reaction, or a rejected claim. Collecting them afterwards is usually impossible.
- The written prescription. From the treating oncologist, naming the medicine, the strength and the dose. No licensed pharmacy may dispense without it.
- A GST tax invoice in the patient's name. It must show the pharmacy's name and drug licence number. An informal bill or a cash slip is not usable for any claim.
- Batch number and expiry date, matching in three places. On the vial, on the carton and on the invoice. If any one of the three disagrees, stop and ask.
- The intact original carton and seal. A carton that has been opened, retaped or relabelled is a reason to refuse the vial, not a detail to overlook.
- Proof of unbroken refrigerated transport. A validated cold box with a temperature record. Ask the pharmacy to note the dispatch time on the invoice.
- Written acceptance from the day-care unit. Obtained before purchase. It records that the unit will infuse a patient-supplied vial and on what conditions.
Keep all six with the treatment file for the whole course, not just the current cycle. Insurers and scheme desks have asked for them months later.
Will insurance, Aarogyasri or CGHS reimburse a vial bought outside?
Often not, and it depends entirely on the scheme. Cashless treatment under Aarogyasri and most empanelled packages is settled between the payer and the hospital. A drug bought privately usually sits outside that package, which means the family has paid twice for the same line item and can recover neither part of it.
Private reimbursement works differently but is no more forgiving. A claim for a high-value biologic generally needs the original invoice in the patient's name, from a licensed pharmacy, tied to the hospital's treatment records for the same date. The most common reason these claims fail is not fraud. It is a bill in a relative's name, a bill with no licence number, or no bill at all.
Two practical steps are worth taking before the first cycle rather than after the third. Ask the hospital billing desk for a written, itemised estimate that separates drug cost from day-care and monitoring charges. Then ask the insurer or scheme desk, in writing, whether a patient-supplied drug is reimbursable under that specific policy or package. Any scheme ceiling quoted verbally is indicative only, as of August 2026, and should be confirmed on paper.
Scheme rules change, and empanelment can be specific to a brand rather than a molecule. Nothing here overrides what a particular insurer or scheme desk tells a family in writing.
Reading further on price, biosimilars and vial safety
- Which Immunotherapy Medicines Have Indian Biosimilars Today? — the legitimate lower-cost route, molecule by molecule, and what is actually marketed here.
- Originator vs Biosimilar: A Price Comparison by Molecule — published, dated figures for the gap families are trying to close.
- Why Cold Chain Matters for Immunotherapy Medicines — what a temperature excursion does to a biologic, and why it cannot be seen.
- Immunotherapy Medicines Explained — the reference section this page sits in, including how pricing and regulatory information is sourced.
- Immunotherapy at CION — the pillar guide to what immunotherapy is, who it suits, and how it is delivered as day care.
This page is editorial reference content. It is not legal advice, not an offer, not a price list, and not a recommendation to use or to source any named product. It makes no comparative quality claim between manufacturers, and it deliberately does not name the brands involved in reported counterfeit cases, because those brands are the victims of that trade rather than its cause. Price figures come from published manufacturer announcements and reported news, named and dated, and are indicative only, as of August 2026 — they are not CION rates. Immunotherapy is administered at CION as day care; response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or cell therapy.